Evidence map›Paper›PMID 30534618›Full record

ArticleHeliyon2018

Comparison of complementary diagnostic tests in cerebrospinal fluid and serum for neurocysticercosis.

Matthew L Romo, Arturo Carpio, R Michael E Parkhouse, María Milagros Cortéz, Richar Rodríguez-Hidalgo

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Subarachnoid neurocysticercosis: emerging concepts and treatment.Current opinion in infectious diseases · 2020
    Review
  3. Neurocysticercosis Diagnosed byCase reports in infectious diseases · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 5 countries.

Matthew L RomoSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
Arturo CarpioGH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
R Michael E ParkhouseInstituto Gulbenkian de Ciência, Oeiras, Portugal.
María Milagros CortézInstituto de Investigaciones Biomédicas "Dr. Francisco J. Triana-Alonso," Facultad de Ciencias de la Salud, Universidad de Carabobo, Venezuela.
Richar Rodríguez-HidalgoInstituto de Investigación en Salud Pública y Zoonosis, Facultad de Medicina Veterinaria y Zootecnia, Universidad Central del Ecuador, Quito, Ecuador.
Central University of Ecuador · ECInstituto Gulbenkian de Ciência · PTUniversity of Carabobo · VEUniversity of Cuenca · ECUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of immunologic tests in the diagnosis of neurocysticercosis (NC) is controversial and few studies have made comparisons among them. The objective of this study was to compare immunological tests in both serum and cerebrospinal fluid (CSF) for the diagnosis of NC. We conducted a case-control study in Cuenca, Ecuador, enrolling patients with NC (N = 24) and matching them with other neurosurgical patients (N = 18). To detect cysticercal antigen, we used an HP10 antigen assay in serum and CSF ("HP10 Ag -serum -CSF") and a commercial antigen assay in serum (apDia, "ELISA-Ag-serum"), and to detect cysticercal DNA, we used a polymerase chain reaction (PCR) assay in CSF ("PCR-CSF"). Assay sensitivities were: HP10 Ag-serum (41.7%, 95% confidence interval [CI] 22.1-63.4), HP10 Ag-CSF (87.5%, 95% CI: 67.6-97.3), ELISA-Ag-serum (62.5%, 95% CI: 40.6-81.2), and PCR-CSF (79.2%, 95% CI: 57.9-92.9). Sensitivities were higher when limiting to participants with extraparenchymal NC. Specificity was 100% for all assays except ELISA-Ag-serum (72.2%). This preliminary study demonstrated the potential usefulness of the PCR and HP10 Ag assay in CSF, especially for extraparenchymal NC; thus, they could be considered as complementary diagnostic tools when neuroimaging is not conclusive.

Indexed as

Evidence-based medicineInfectious diseaseNeurology

Identifiers

PMID30534618
PMCPMC6278713
OpenAlexW2903057257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.